REG - Venture Life Group - Posting of Annual Report

Venture LifeAnnouncement

19/06/2024 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240619:nRSS1018Ta&default-theme=true

RNS Number : 1018T  Venture Life Group PLC  19 June 2024

19(th) June 2024

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Posting of Annual Report

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the international self-care market, announces
that the Company's Annual Report and Accounts for the year ended 31 December
2023 are available to be viewed on the Venture Life website:
www.venture-life.com (http://www.venture-life.com) , and that copies have been
sent to shareholders.

 

For further information, please contact:

 

Venture Life Group
PLC
                +44 (0) 1344 578004

 

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)
          +44 (0) 20 7720 0500

 

Stephen Keys/Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

 

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, and Sweden, the Group's
product portfolio includes some key products such as the Balance Active range
in the area of women's intimate healthcare, the Earol® product line in ENT
care, the Lift and Glucogel product ranges for energy and glucose management
and hypoglycaemia, the UltraDEX and Dentyl oral care product ranges, products
for fungal infections and proctology, and dermo-cosmetics for addressing the
signs of ageing. Its products are sold in over 90 countries worldwide.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSQKCBQNBKDBAD